Fox Chase Cancer Center and Oryzon Genomics to Collaborate on Trial Investigating Safety and Efficacy of Iadademstat in Neuroendocrine and Small Cell Carcinomas
PHILADELPHIA (November 17, 2022)—Fox Chase Cancer Center and Oryzon Genomics S.A. will work together to test the safety and efficacy of the drug iadademstat in patients with pulmonary and extrapulmonary neuroendocrine carcinomas (NECs), which are rare and heterogeneous cancers arising from neuroendocrine cells, and small cell lung cancer (SCLC).